- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07932717
Comprehensive Lung Health (CLUES)
Comprehensive Lung Health Screening and Its Utility for Early Risk and Disease Stratification
Respiratory illnesses are a leading cause of morbidity and mortality worldwide, yet their prevalence in the general population remains poorly characterized. Computed tomography (CT) is the most effective diagnostic tool for identifying respiratory illnesses that cause changes to the lung parenchyma, such as pulmonary infections, fibrosis, and nodules. The diagnostic power of CT led the US Preventive Services Task Force (USPSTF) to issue lung cancer screening guidelines. In this prospective, observational cohort study, the study team will recruit 10,000 individuals aged 21 to 85 years, stratified into three cohorts: Cohort 1 (Medical Indication Group), Cohort 2 (Guideline-Based Screening Group), and Cohort 3 (Asymptomatic Research Low-Dose CT [LDCT] Group). The primary analysis will estimate the baseline cross-sectional prevalence of LDCT-detectable pulmonary findings in Cohort 3. Secondary analyses will compare baseline LDCT findings across all three cohorts and evaluate baseline associations between risk/exposure variables and CT findings. Exploratory follow-up analyses will use clinical data from the electronic health record (EHR), as available, for up to 5 years after the baseline/index CT. This study has the potential to transform health screening strategies, reduce disease burden, and improve health outcomes across diverse populations.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Lindsay Summers
- Telefoonnummer: 312-921-2957
- E-mail: lindsay.summers@nm.org
Studie Locaties
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern Medicine
-
Hoofdonderzoeker:
- Ankit Bharat, MD
-
Contact:
- Lindsay Summers
- Telefoonnummer: 312-921-2957
- E-mail: lindsay.summers@nm.org
-
Onderonderzoeker:
- Momen Wahidi, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
All Cohorts:
•Adults 21 through 85 years of age.
Cohort 1:
•Clinical indication for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 activities are routine clinical care; research activity is secondary data use.
Cohort 2:
•Individuals who currently meet USPSTF criteria for LDCT lung cancer screening. Cohort 2 activities are routine clinical care; research activity is secondary data use.
Cohort 3:
- Asymptomatic individuals who:
- Do not have a clinical indication for chest CT
- Do not meet current USPSTF criteria for LDCT lung cancer screening
- Able to provide informed consent
Exclusion Criteria:
All Cohorts:
•Individuals below the age of 21 and above the age of 85.
Cohort 3:
- Meets USPSTF guideline-based indications for LDCT lung cancer screening or has a clinical indication for chest CT.
- Any chest CT within the prior 2 years
- Pregnancy
- In active surveillance or treatment for a current cancer diagnosis, or a recent cancer diagnosis requiring intervention within 5 years of the baseline assessment.
- Unable to provide informed consent or lacks decision-making capacity
- McGaw medical students, residents, and fellows, consistent with NU/FSM policy, to reduce coercion or undue influence. Employees may participate only under the safeguards described in the vulnerable populations section.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Screening
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Cohort 1 (Medical Indication Group)
Adults 21 through 85 years of age with a clinical reason for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 participants undergo CT and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization. |
|
|
Geen tussenkomst: Cohort 2 (Guideline-Based Screening Group)
Adults 21 through 85 years of age who meet current USPSTF criteria for LDCT lung cancer screening. Cohort 2 participants undergo screening and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization. |
|
|
Actieve vergelijker: Cohort 3 (Asymptomatic Research LDCT Group)
Adults 21 through 85 years of age who are asymptomatic, do not have a clinical indication for chest CT, and do not meet current USPSTF lung cancer screening criteria. Cohort 3 participants will provide informed consent and HIPAA authorization before undergoing a single LDCT of the chest billed to the study. |
A low-dose CT scan is an X-ray procedure where a high-speed computer is used to make multiple images of your chest area using the least amount of radiation possible without reducing the diagnostic quality of the exam.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary Endpoint
Tijdsspanne: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Baseline prevalence of CT-detectable pulmonary abnormalities in Cohort 3. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary Endpoint 1
Tijdsspanne: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Comparative baseline prevalence of pulmonary findings across Cohorts 1, 2, and 3. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 2
Tijdsspanne: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Prevalence and reported severity of coronary artery calcification in Cohort 3 and across cohorts, using the final radiology report categories, such as absent/present or none/mild/moderate/severe when available. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 3
Tijdsspanne: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Prevalence of bone-density-related abnormalities or vertebral compression fracture findings across all three cohorts using the final radiology report terminology. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 4
Tijdsspanne: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Associations between baseline defined variables and LDCT-detectable findings. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 5
Tijdsspanne: 5 years
|
EHR-derived outcomes for up to 5 years after baseline/index LDCT, including clinically documented diagnoses, additional imaging, procedures, treatments, and mortality as available. |
5 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Exploratory Endpoint 1
Tijdsspanne: 6 years
|
Subgroup analyses by age, sex, race/ethnicity, smoking status, and exposure categories. |
6 years
|
|
Exploratory Endpoint 2
Tijdsspanne: 6 years
|
Exploratory prediction models if event counts support model development. |
6 years
|
|
Exploratory Endpoint 3
Tijdsspanne: 6 years
|
Descriptive analyses of downstream clinical evaluation after baseline CT findings. |
6 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ankit J Bharat, MD, Northwestern Medicine Canning Thoracic Institute
- Hoofdonderzoeker: Momen J Wahidi, MD, Northwestern Medicine Canning Thoracic Institute
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STU00223477
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Upon PI approval, de-identified, coded data may be shared with other investigators conducting IRB-approved projects to establish a longitudinal data repository to support future IRB-approved research on early detection, prevention, and management of pulmonary and cardiothoracic conditions. Genetic testing, biospecimen collection, quantitative imaging re-analysis, or other analyses are not currently planned. Recipients will be required to adhere to institutional data protection standards.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .